| Today’s Big NewsMay 21, 2025 |
|
Thursday, May 29, 2025 | 11am ET / 8am PT While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more.
|
|
| By Conor Hale The medtech giant said it aims to complete the spinoff within the next 18 months, with the goal of taking the new company public through an IPO. |
|
|
|
By Nick Paul Taylor Moderna has pulled the filing for FDA approval of its flu/COVID combination vaccine. The biotech plans to resubmit later this year with the phase 3 flu vaccine efficacy data the agency wants to see. |
By Kevin Dunleavy With the withdrawal of the U.S. from the World Health Organization, the United Nations-backed agency has lost its top donor. Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 Danish kroner ($58 million) from this year to 2028. China also has stepped up, pledging $500 million over the next five years. |
By Angus Liu Johnson & Johnson has won the support of an FDA expert panel in its bid to make Darzalex the first treatment for an early form of multiple myeloma despite uncertainties raised by regulators. |
|
Thursday, June 5, 2025 | 11am ET / 8am PT Off-target binding can be a significant hurdle in the development of antibody-based therapies, with limitations of conventional screening methods being a key factor. Join our webinar to learn more about the latest approaches to specificity profiling. Register now.
|
|
By James Waldron Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the molecular glue biotech. |
By Fraiser Kansteiner The Supreme Court of Korea has sided with SK in an ongoing patent feud with Pfizer, ruling that the Korean company did not violate a composition patent on Pfizer’s pneumococcal shot Prevnar 13 by shipping components and finished research doses of its own 13-valent immunization, PCV13, to Russia. |
By Conor Hale The Hong Kong-based company—founded in 2015 as a UCLA spinout—said it has already conducted over 8 million lab tests worldwide. |
By James Waldron Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has now shared the data to back up its belief that the therapy still has promise. |
By Andrea Park As it continues to ramp up sales of its attention-deficit/hyperactivity disorder drug Qelbree, Supernus Pharmaceuticals is getting Busy to raise awareness of the med among an often-overlooked group—Busy Philipps, that is. |
By Darren Incorvaia A team of scientists has harnessed CRISPR technology to identify a protein that helps cancers spread to bone tissue, opening the door for potential therapies to prevent the common and painful disease progression. |
By Darren Incorvaia After a two-year pilot period, Equitable Breakthroughs in Medicine Development has officially launched a nonprofit meant to expand access to clinical trials. |
By Zoey Becker Pfizer linked up with U.K. LGBTIQ+ cancer advocacy group OUTpatients to break down some barriers the community faces in cancer care and remind doctors that their patients are more than their cancer diagnoses. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold. |
|
|---|
|
|
|
Wednesday, June 11, 2025 | 11am ET / 8am PT Join us for a deep dive into the strategies and best practices for maximizing valuation by improving productivity in modern clinical trials. We'll discuss key ways to achieve tangible productivity gains, accelerate timelines, and avoid costly protocol amendments or clinical failures. Register now to learn expert tips for maximizing efficiency and effectiveness.
|
|
| WhitepaperDon’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
| WhitepaperLearn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
